IDNA stock forecast, quote, news & analysis

Key Takeaways

• IDNA has climbed roughly 29% over the last 30 days, from about $32 to $41, propelled by a single major clinical catalyst in the genomics and immunology space.
• The quarterly trend is even stronger, with the fund up approximately 39% over the trailing three months.
• The primary driver was a positive late-stage trial readout from Moderna (MRNA) and Merck (MRK), which lifted the broader biotech complex.
• The fund's concentrated healthcare and biotechnology exposure makes it highly sensitive to clinical events and shifts in risk appetite.

iShares Genomics Immunology and Healthcare ETF (IDNA) Overview and Portfolio Exposure

The iShares Genomics Immunology and Healthcare ETF (IDNA) is a passively managed, non-diversified thematic fund that seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. The index holds developed and emerging market companies positioned to benefit from long-term growth and innovation in genomics, immunology, and bioengineering. The fund carries a net expense ratio of 0.47% and holds roughly 55 companies.

Portfolio exposure is overwhelmingly concentrated in healthcare, which represents close to 90% of assets, with biotechnology alone accounting for roughly three-quarters of the fund. Top holdings include Twist Bioscience (TWST), Revolution Medicines (RVMD), Moderna (MRNA), Bayer, Genmab, Regeneron Pharmaceuticals (REGN), Incyte (INCY), Takeda Pharmaceutical, Vertex Pharmaceuticals (VRTX), and Merck (MRK). Geographically, the United States is the largest allocation at roughly 64%, followed by France, Japan, Germany, and Denmark.

This structure explains the fund's recent volatility: because IDNA is concentrated in clinical-stage and small- to mid-cap biotechnology companies alongside large-cap pharmaceutical names, a single successful late-stage trial can trigger outsized moves across the entire portfolio.

iShares Genomics Immunology and Healthcare ETF (IDNA) Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, IDNA has risen approximately 29%, advancing from about $32 to roughly $41. The move was not gradual; much of the gain was concentrated in a single session in which the fund jumped more than 13% on trading volume roughly 2.8 times its average.

The quarterly picture is even more pronounced. Over the trailing three months, IDNA has climbed approximately 39%, from about $30 to its current level. The trend has been event-driven and volatile rather than a steady, low-volatility grind, with the fund consolidating through the mid-$30s before breaking sharply higher on the late-stage clinical catalyst.

What Drove IDNA Price in the Last 30 Days

The dominant catalyst was a positive Phase III readout in oncology. Moderna (MRNA) and Merck (MRK) announced that their personalized mRNA neoantigen therapy combined with Keytruda met its primary endpoint in a pivotal melanoma trial. Moderna shares surged nearly 177% on the news, while Merck rose more than 12%.

Because Moderna and Merck together represent a meaningful share of IDNA's assets, the announcement translated directly into fund performance. The news also re-rated the broader precision-medicine theme, lifting gene-editing and AI-driven drug discovery names held in the portfolio, including Twist Bioscience and related platform companies. The rally reflected a decline in perceived risk across similar research pipelines, as success in one novel therapeutic modality tended to lower the perceived risk for the entire category. This sentiment-driven broadening helped carry the fund well beyond the direct contribution of the two headline stocks.

What Drove IDNA Performance Over the Last Quarter

The three-month advance reflects a broader rotation back into biotechnology after a period of relative underperformance. Improving risk appetite toward rate-sensitive growth segments supported the sector, and the positive clinical data provided the trigger that converted building momentum into an outsized move.

Institutional positioning also played a role. Biotechnology has been highlighted as a way to diversify away from crowded technology exposure, and the sector had been delivering positive returns for several months before the trial announcement. Favorable valuations relative to the broader market and renewed merger-and-acquisition activity expectations reinforced the shift. The strength in large-cap holdings such as Moderna and Merck was complemented by a broad recovery across mid- and small-cap clinical-stage companies, which are heavily represented in IDNA's portfolio.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance characteristics. It is designed to surface trending securities, breakout candidates, and emerging opportunities more efficiently than manual screening. For investors monitoring themes like genomics and immunology, the AI Screener can help identify securities exhibiting similar momentum or technical setups. Explore the AI Screener to refine your research process.

IDNA ETF Outlook: What Investors Should Watch Next

Several factors will shape IDNA's trajectory in the months ahead. Clinical catalysts remain the most important variable, as late-stage trial readouts, regulatory approvals, and data disclosures across the portfolio's genomics and immunology names can drive sharp moves in either direction. Interest rate expectations also matter, given biotechnology's sensitivity to financing conditions and the discounted value of future cash flows.

Investors should monitor merger-and-acquisition activity, which tends to accelerate when clinical risk declines and could support valuations across the fund's mid- and small-cap holdings. Sector capital flows and the durability of the rotation away from crowded technology exposure will also influence performance. On the risk side, the fund's concentration in biotechnology and clinical-stage companies leaves it exposed to volatility, binary data outcomes, and broader risk-off episodes. The pace of any valuation re-rating relative to the broader biotech universe is another theme to follow.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations